Devices diagnostics discovery tools drug delivery enabling technology equipment facilities genomics industrial chemicals nanotechnology oligonucleotide orphan drug packaging peptides processes proteomics radio/chemo-therapy recombinant dna regenerative medicine research services research supplies rna therapeutics screening small molecules software tools stem cells chapter 6 – hematology dealmaking by indication 6. 1. Introduction 6. 2. Deals by therapeutic indication hematology anemia iron deficiency blood substitute neutropenia polycythemia thalassemia thrombocytopenia vitamin k deficiency von-willebrand disease chapter 7 – partnering resource center 7. buy viagra online canada no prescription viagra for sale viagra without a doctor prescription buy generic viagra buy cheap viagra buy viagra generic viagra buy generic viagra buy viagra online buy cheap viagra 1. Online partnering 7. 2. Partnering events 7. 3. Further reading on dealmaking appendices appendix 1 – directory of hematology deals by company a-z 2007-2012 appendix 2 – directory of hematology deals by deal type 2007-2012 appendix 3 – directory of hematology deals by stage of development 2007-2012 appendix 4 – directory of hematology deals by technology type 2007-2012 appendix 5 – deal type definitions about wildwood ventures current partnering current agreements recent titles from currentpartnering order form – reports table of figures figure 1: hematology partnering since 2007 figure 2: bigpharma – top 50 – hematology deals 2007 to 2012 figure 3: bigpharma hematology deal frequency – 2007 to 2012 figure 4: inactive bigpharma in hematology 2007-2012 figure 5: hematology partnering by deal type since 2007 figure 6: hematology partnering by industry sector since 2007 figure 7: hematology partnering by stage of development since 2007 figure 8: hematology partnering by technology type since 2007 figure 9: hematology partnering by hematology target since 2007 figure 10: hematology deals with a headline value figure 11: hematology deal headline value distribution, us$million – discovery stage figure 12: hematology deal headline value distribution, us$million – preclinical stage figure 13: hematology deal headline value distribution, us$million – phase i stage figure 14: hematology deal headline value distribution, us$million – phase ii stage figure 15: hematology deal headline value distribution, us$million – phase iii stage figure 16: hematology deal headline value distribution, us$million – regulatory stage figure 17: hematology deal headline value di.

 

HVA ER VI I THORESEN & CO SPESIALISTER PÅ? JO, VI PRODUSERER KLÆR, TEKSTILER, BAGGER, SEKKER OG ALL ANNEN TEKSTILBASERT PRODUKSJON FOR AKTØRER SOM ØNSKER PRODUKSJONSHJELP.  DETTE GJØR VI FOR DET MESTE I KINA OG INDIA. PRODUKSJONSHÅNDTERING HAR VI BRED OG LANG ERFARING MED -  I KINA HAR VI HOLDT PÅ SIDEN 1952.  DETTE GJØR OSS TROLIG TIL DET FIRMA MED DEN LENGSTE ERFARING MED HANDEL PÅ KINA. VI TILBYR MED STOLTHET VÅRE TJENESTER!